On March 3, 2017, the US Food and Drug Administration (FDA) approved desmopressin nasal spray (Noctiva) for the “treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.”1 According to the product manufacturer, Serenity Pharmaceuticals, nocturia is a common condition affecting “over 89 million adults in the U.S.”2
Fralick M, Kesselheim AS. FDA Approval of Desmopressin for Nocturia. JAMA. 2017;317(20):2059–2060. doi:10.1001/jama.2017.4316
Customize your JAMA Network experience by selecting one or more topics from the list below.